Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd (CANF)

Can-Fite Biopharma Ltd (CANF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,448
  • Shares Outstanding, K 15,414
  • Annual Sales, $ 2,030 K
  • Annual Income, $ -9,590 K
  • 60-Month Beta 1.57
  • Price/Sales 16.84
  • Price/Cash Flow N/A
  • Price/Book 3.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.36
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +76.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +21.71%
on 07/13/20
2.95 -27.80%
on 07/27/20
+0.29 (+15.76%)
since 07/10/20
3-Month
1.61 +32.30%
on 06/11/20
2.95 -27.80%
on 07/27/20
+0.38 (+21.71%)
since 05/12/20
52-Week
1.08 +97.22%
on 02/12/20
4.95 -56.97%
on 12/02/19
-0.51 (-19.32%)
since 08/12/19

Most Recent Stories

More News
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)
Thinking about buying stock in Can Fite Biopharma, RTI Surgical Holdings, JetBlue Airways, iBio Inc, or Sunrun Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, RTIX, JBLU, IBIO, and RUN.

CANF : 2.13 (-1.84%)
IBIO : 2.45 (-11.23%)
RUN : 44.94 (+6.07%)
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced...

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)
Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

, /PRNewswire/ --   – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...

RHHBY : 43.3700 (+2.85%)
XYNO : 0.2001 (unch)
CANF : 2.13 (-1.84%)
ONCY : 1.6900 (-9.63%)
ONC.TO : 2.22 (-9.76%)
Glaucoma Drugs Market Opportunities, Demands and Growth Revenue by 2025 | Brandessence Market Research Report

AERI : 12.40 (+0.81%)
AGN : 193.02 (+0.02%)
CANF : 2.13 (-1.84%)
ITEK : 3.04 (-5.00%)
MRK : 82.68 (+2.19%)
NMUS : 0.6500 (-9.52%)
NVS : 84.93 (+3.03%)
OCAT : 8.47 (+0.12%)
OCUL : 8.24 (+1.73%)
OHRP : 5.39 (+30.19%)
PRGO : 53.22 (+0.47%)
PFE : 38.33 (+1.43%)
SNPHF : 17.5000 (+2.04%)
SCMP : 18.05 (+0.28%)
TEVA : 11.64 (-0.68%)
VRX.TO : 30.80 (-3.33%)
Can-Fite Announces $8.0 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced...

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)
Thinking about buying stock in Can Fite Biopharma, Extraction Oil & Gas, Macy's, New Age Beverages, or GNC Holdings?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, XOG, M, NBEV, and GNC.

CANF : 2.13 (-1.84%)
GNC : 0.5500 (unch)
M : 7.12 (+1.28%)
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.

--

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced...

CANF : 2.13 (-1.84%)
CFBI : 7.01 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CANF with:

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

2nd Resistance Point 2.22
1st Resistance Point 2.17
Last Price 2.13
1st Support Level 2.09
2nd Support Level 2.06

See More

52-Week High 4.95
Fibonacci 61.8% 3.47
Fibonacci 50% 3.01
Fibonacci 38.2% 2.56
Last Price 2.13
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar